A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells
Edward Seung,Zhen Xing,Lan Wu,Ercole Rao,Virna Cortez-Retamozo,Beatriz Ospina,Liqing Chen,Christian Beil,Zhili Song,Bailin Zhang,Mikhail Levit,Gejing Deng,Andrew Hebert,Patrick Kirby,Aiqun Li,Emma-Jane Poulton,Rita Vicente,Audrey Garrigou,Peter Piepenhagen,Greg Ulinski,Michele Sanicola-Nadel,Dinesh S. Bangari,Huawei Qiu,Lily Pao,Dmitri Wiederschain,Ronnie Wei,Zhi-yong Yang,Gary J. Nabel
DOI: https://doi.org/10.1038/s41586-022-04439-0
IF: 64.8
2022-02-23
Nature
Abstract:Effective antitumour immunity depends on the orchestration of potent T cell responses against malignancies1. Regression of human cancers has been induced by immune checkpoint inhibitors, T cell engagers or chimeric antigen receptor T cell therapies2–4. Although CD8 T cells function as key effectors of these responses, the role of CD4 T cells beyond their helper function has not been defined. Here we demonstrate that a trispecific antibody to HER2, CD3 and CD28 stimulates regression of breast cancers in a humanized mouse model through a mechanism involving CD4-dependent inhibition of tumour cell cycle progression. Although CD8 T cells directly mediated tumour lysis in vitro, CD4 T cells exerted antiproliferative effects by blocking cancer cell cycle progression at G1/S. Furthermore, when T cell subsets were adoptively transferred into a humanized breast cancer tumour mouse model, CD4 T cells alone inhibited HER2+ breast cancer growth in vivo. RNA microarray analysis revealed that CD4 T cells markedly decreased tumour cell cycle progression and proliferation, and also increased pro-inflammatory signalling pathways. Collectively, the trispecific antibody to HER2 induced T cell-dependent tumour regression through direct antitumour and indirect pro-inflammatory/immune effects driven by CD4 T cells.
multidisciplinary sciences